Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood (2025) 146 (Supplement 1): 664.

https://doi.org/10.1182/blood-2025-664

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2025-1852

Published: 2025

Journal Articles

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Blood (2025) 146 (Supplement 1): 893.

https://doi.org/10.1182/blood-2025-893

Published: 2025

Journal Articles

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Sairah Ahmed, Jinwen Cao, Matthew Mei, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Mohamed Iburahim Haja Maideen, Omnia Farahat, Adam Braun, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2025-1844

Published: 2025

Journal Articles

Pharmacologic drugging of BCL-2 during manufacturing restores T cell fitness and enhances CART efficacy

Nada Aboelella, Ryan Park, Erting Tang, Nicholas Asby, Joshua Ho, Tony Pan, Sidney Wang, Lishi Xie, Justin Kline, Peter Riedell, Jun Huang, James LaBelle

Blood (2025) 146 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2025-1047

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani, Peter Riedell, Ajay Gopal, Leona Holmberg, Qian Wu, Sonali Smith, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2025-5483

Published: 2025

Journal Articles

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Sairah Ahmed, Matthew Mei, Jinwen Cao, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Omnia Farahat, Mohamed Iburahim Haja Maideen, Adam Braun, Daniel Reef, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 5938.

https://doi.org/10.1182/blood-2025-5938

Published: 2025

Journal Articles

Low skeletal muscle mass and cancer cachexia among patients with multiple myeloma undergoing CAR-T cell therapy

Samuel Yates, Abigail Sneider, Claire Wild, Ishan Roy, Kayla Beck, Ioanna Karras, Varun Akella, Nicholas Feinberg, Karteek Popuri, Mirza Faisal Beg, Peter Riedell, Mariam Nawas, Benjamin Derman

Blood (2025) 146 (Supplement 1): 5780.

https://doi.org/10.1182/blood-2025-5780

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell

Blood (2025) 146 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2025-2707

Published: 2025

Journal Articles

Policy and systems solutions to expand timely access to CAR T-cell therapy: Findings from a national survey of oncology professionals

Caroline Offit, Nakhle Saba, Peter Riedell, Arnela Kajdic Tarantino, Nicole Colwell, Kimberly Demirhan, Molly Kisiel, Farrukh Awan

Blood (2025) 146 (Supplement 1): 2638.

https://doi.org/10.1182/blood-2025-2638

Published: 2025

Journal Articles

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 784.

https://doi.org/10.1182/blood-2025-784

Published: 2025

Journal Articles

Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database

Kenneth R. Carson, MD, Ryan Lynch, MD, Peter Riedell, MD, Ryan P. Roop, MD, Arun Ganti, MPHS, Weijan Liu, MS, Chadi Nabhan, MD, FACP, Tanya Wildes, MD, Kristen M. Sanfilippo, MD, Graham A Colditz, M.D., Dr.PH.

Blood (2012) 120 (21): 968.

https://doi.org/10.1182/blood.V120.21.968.968

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Pharmacologic drugging of BCL-2 during manufacturing restores T cell fitness and enhances CART efficacy

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Low skeletal muscle mass and cancer cachexia among patients with multiple myeloma undergoing CAR-T cell therapy

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Policy and systems solutions to expand timely access to CAR T-cell therapy: Findings from a national survey of oncology professionals

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only